05/12/22 10:00 AMNasdaq : SRRA clinical triallow floatSierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual MeetingSierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association. “We are excited and honored to have the MOMENTUM data selected for an oral presentation at EHA...RHEA-AIneutral
05/06/22 7:00 AMNasdaq : SRRA low floatSierra Oncology Reports First Quarter 2022 ResultsSierra Oncology, Inc., a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. We are working to continue to progress our timeline and our NDA submission remains on track for later this quarter,” said...RHEA-AIneutral
05/05/22 4:05 PMNasdaq : SRRA low floatSierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company’ s Board of Directors, under Sierra Oncology’ s 2018 Equity Inducement Plan. The options have an exercise price of $54.61 per share,...RHEA-AIvery positive
04/25/22 8:00 AMNasdaq : SRRA managementlow floatRayzeBio Appoints Angie You, Ph.D., to its Board of DirectorsDr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. I have known Ken for over 20 years and am excited to partner with him, the RayzeBio board and management team to support the Company in its ambitious goals,” said Dr....RHEA-AIneutral
04/13/22 5:41 PMNasdaq : ATRS, OBNK, SRRA SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNKHalper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:Sierra Oncology , Inc. (NASDAQ: SRRA)'s sale toRHEA-AIneutral
04/13/22 7:53 AMNasdaq : SRRA low floatSRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to ShareholdersHalper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Sierra Oncology, Inc. to GlaxoSmithKline plc for $55.00 per share in cash is fair to Sierra Oncology shareholders. Halper Sadeh encourages Sierra Oncology shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at...RHEA-AIneutral
04/13/22 2:05 AMNasdaq, NYSE : SRRA, GSK acquisitionlow floatGSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bnGlaxoSmithKline plc and Sierra Oncology, Inc today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California- based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate...RHEA-AIpositive
04/06/22 6:00 PMNasdaq : SRRA low floatSierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company’ s Board of Directors, under Sierra Oncology’ s 2018 Equity Inducement Plan. The options have an exercise price of $33.76 per share,...RHEA-AIvery positive
03/11/22 7:00 AMNasdaq : SRRA conferenceslow floatSierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare ConferenceSierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32 nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview...RHEA-AIneutral
03/10/22 7:00 AMNasdaq : SRRA low floatSierra Oncology Reports 2021 Year End ResultsSierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021. This year, we’ ll be focused on our regulatory submission and the continued build out of our commercial team to prepare...RHEA-AIneutral